Our philosophical approach to working with the medical community to conduct clinical trials is built on evidence-based medicine. We believe in playing a leadership role by collecting solid data that helps inform decision-making. With this conviction, we have set a standard of scientific rigor that is unmatched in our field. The data must be relevant, complete and shared openly with clinicians. We must work with clinicians to design the most objective, thorough, rigorous and controlled trials possible. And we must be willing to stand by the unvarnished results. We've invested significantly to establish preclinical and clinical trials as a highly successful and respected core competency at Boston Scientific. We now have more than 450 employees in our clinical sciences organization. They currently oversee more than 140 ongoing preclinical studies and enrolled more than 40,000 patients into pre- and post-approval clinical trials in 2005.
HORIZONS-AMI Trial 12-Month Outcomes(PDF)
SYNTAX Trial 12-Month Left Main Subset Data(PDF)
SYNTAX Trial 12-Month 3-Vessel Disease Subset Data(PDF)
SYNTAX Trial 12-Month Outcomes in Subset of Patients with Diabetes(PDF)
SYNTAX Trial 12-Month Outcomes(PDF)
TAXUS IV US Pivotal Trial – Final 5-Year Outcomes (PDF)
TAXUS Stent Meta-Analysis 5-Year(PDF)
Drug-Eluting Stent Clinical Programs (PDF)
TAXUS Liberté Trial Data (PDF)
TAXUS I Randomized Feasibility Trial (PDF)
TAXUS II International Efficacy Trial (PDF)
TAXUS III In-Stent Restenosis Feasibility Trial (PDF)
TAXUS IV US Pivotal Trial (PDF)
TAXUS V de novo Lesion Pivotal Expansion Trial (PDF)
TAXUS V ISR US Randomized Pivotal Trial (PDF)
TAXUS VI Randomized International Complex Trial (PDF)
ARRIVE 1 US Safety Registry* (PDF)
ARRIVE 2 US Safety Registry
MILESTONE II International Registry (PDF)
WISDOM International Registry (PDF)
BLAZE Clinical Registry Summary (PDF)
BEACH
TAXUS ATLAS Trial (PDF)
SYNTAX
CABERNET
